13929-35-6 Usage
Uses
Used in Pharmaceutical Industry:
Rifamycin, 4-O-(carboxymethyl)is used as an antibacterial agent for the treatment of various bacterial infections. Its application is particularly relevant in the context of multi-drug resistant bacteria, where traditional antibiotics may be less effective. The compound's ability to target bacterial RNA polymerase provides a distinct advantage in combating resistant strains.
Additionally, Rifamycin B (Rifaximin EP Impurity B), another Rifamycin (R508200) derivative, is also used as an antibacterial agent. This further highlights the versatility and utility of the Rifamycin family in the development of novel antibacterial drugs to address the growing challenge of antibiotic resistance.
Purification Methods
Rifamycin B forms yellow needles from *C6H6. Its solubilities are: H2O (0,027%), MeOH (2.62%) and EtOH (0.44%). It has UV max at 223, 304 and 245nm (A 1cm 555, 275 and 220). [Oppolzer & Prelog Helv Chim Acta 56 2287 1973, Oppolzer et al. Experientia 20 336 1964, X-ray: Brufani et al. Experientia 20 339 1964.]
Check Digit Verification of cas no
The CAS Registry Mumber 13929-35-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,9,2 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13929-35:
(7*1)+(6*3)+(5*9)+(4*2)+(3*9)+(2*3)+(1*5)=116
116 % 10 = 6
So 13929-35-6 is a valid CAS Registry Number.
InChI:InChI=1/C39H49NO14/c1-17-11-10-12-18(2)38(49)40-24-15-26(51-16-27(42)43)28-29(34(24)47)33(46)22(6)36-30(28)37(48)39(8,54-36)52-14-13-25(50-9)19(3)35(53-23(7)41)21(5)32(45)20(4)31(17)44/h10-15,17,19-21,25,31-32,35,44-47H,16H2,1-9H3,(H,40,49)(H,42,43)/b11-10+,14-13+,18-12+/t17-,19-,20+,21-,25-,31-,32+,35+,39-/m0/s1
13929-35-6Relevant academic research and scientific papers
Deciphering the late steps of rifamycin biosynthesis
Qi, Feifei,Lei, Chao,Li, Fengwei,Zhang, Xingwang,Wang, Jin,Zhang, Wei,Fan, Zhen,Li, Weichao,Tang, Gong-Li,Xiao, Youli,Zhao, Guoping,Li, Shengying
, (2018/06/26)
Rifamycin-derived drugs, including rifampin, rifabutin, rifapentine, and rifaximin, have long been used as first-line therapies for the treatment of tuberculosis and other deadly infections. However, the late steps leading to the biosynthesis of the industrially important rifamycin SV and B remain largely unknown. Here, we characterize a network of reactions underlying the biosynthesis of rifamycin SV, S, L, O, and B. The two-subunit transketolase Rif15 and the cytochrome P450 enzyme Rif16 are found to mediate, respectively, a unique C-O bond formation in rifamycin L and an atypical P450 ester-to-ether transformation from rifamycin L to B. Both reactions showcase interesting chemistries for these two widespread and well-studied enzyme families.
Synthesis of aminoshikimic acid
Guo, Jiantao,Frost
, p. 1585 - 1588 (2007/10/03)
5-Amino-5-deoxyshikimic acid (aminoshikimic acid) was synthesized from glucose using recombinant Amycolatopsis mediterranei and also synthesized by a tandem, two-microbe route employing Bacillus pumilus and recombinant Escherichia coli.
